Kornimate/medical-research-clean huggingface dataset:
predictors of acute kidney injury in critically ill children admitted to picu.

Conditions: Acute Kidney Injury

Summary: predictors of acute kidney injury in critically ill children admitted to picu during one year.

acute kidney injury (aki) is defined by a sudden loss of excretory kidney function. aki is part of a range of conditions summarized as acute kidney diseases and disorders (akd), in which slow deterioration of kidney function or persistent kidney dysfunction is associated with an irreversible loss of kidney cells and nephrons, which can lead to chronic kidney disease (ckd). aki is determined by increased serum creatinine levels \>0.3 mg/dl (a marker of kidney excretory function) and reduced urinary output \ 3 months is referred to as chronic kidney disease (ckd). acute kidney injury (aki) is associated with poor outcome in critically ill children. the reported incidence rate of aki in children admitted to pediatric intensive care units (picus) ranges from 8% and 89% worldwide. stage 1 was identified in 24.24% of the aki cases, stage 2 in 31.03% and stage 3 in 44.71%. the most prevalent cause of aki was represented by prerenal aki in 85.64% of the cases, followed by 12.16% renal causes respectively 2.18% postrenal causes. symptoms of an aki come on suddenly, over the course of hours or days. they depend on the underlying cause, but some of the most common symptoms include hematuria, fever, rash, bloody diarrhea, severe vomiting, abdominal pain, no urine output or high urine output, pale skin. oedema, puffy eyes and detectable abdominal mass. there are many predisposing factors that lead to aki for such as gastroenteritis, presence of infection, sepsis, shock, cardiac disease, mechanical ventilation hypoxia and coagulopathy are important predictors for aki. despite significant developments in the management of aki, the overall mortality rate of patients with aki has not improved dramatically. the most widely available studies deal primarily with aki, reporting mortality rates between 11% and 63% in pediatric patients. outcomes among children who develop acute kidney injury (aki). children who develop aki while hospitalized are at risk for poorer short- and mid/long-term outcomes. across both acute and critical care populations, aki is associated with longer lengths of stay, non-recovery of baseline renal function, and chronic renal disease including proteinuria, hypertension, and chronic kidney disease (ckd)

Eligibility criteria:
inclusion criteria: * children aged from month to 18 years admitted to picu between april 2024 to may 2025. exclusion criteria: * exclusion of children aged below 1 month and older than 18 years. * chronic kidney disease. * renal malformations.
mindfulness intervention in orthopedic trauma patients

Conditions: Pain; Anxiety

Summary: this project a single-site 3-arm parallel group randomized clinical trial conducted at a tertiary level 1 trauma center among patients undergoing operative fixation of a lower extremity fracture.


Eligibility criteria:
inclusion criteria: * age at presentation between 18 and 65 years * acute lower extremity fracture to be operatively managed * glasgow coma scale of 15 * english speaking * willingness to participate in study exclusion criteria: * cognitive impairment * pregnant or lactating woman * current incarceration * planned secondary procedure
mobile applet for weight management in obese heart failure patients

Conditions: Heart Failure; Overweight and Obesity; Weight Loss; Heart Failure With Reduced Ejection Fraction

Summary: the objective of this clinical trial is to investigate the effect of weight reduction through a diet management application and an intelligent weight scale on a composite cardiovascular endpoint in obese patients with heart failure. the main questions are: does the use of a diet management app and intelligent weight scale reduce 1-year all-cause mortality, heart failure hospitalization, and first heart failure hospital stay? does the use of a diet management app and intelligent weight scale improve the outcomes of assessment of heart failure frailty and quality of life for heart failure? researchers will compare using the fully functional diet management app and intelligent weight scale to using the limitedly functional app and intelligent weight scale to see if the app works to improve heart failure conditions. participants will: use the diet management app at every meal and the intelligent weight scale every day for 12 months, and visit the clinic at 12 months for checkups.

obesity is one of the major risk factors for heart failure. current guidelines for heart failure emphasize that severe obesity is associated with a poor prognosis in patients with heart failure, but there are no recommended effective interventions. caloric restriction alone, increased exercise, the use of weight-loss drugs, and bariatric surgery are not appropriate for obese patients with heart failure. whether obese heart failure patients with reduced ejection fraction (hfref) can benefit from weight loss treatment has not been evaluated in randomized controlled trials so far. this study combines caloric restriction with lifestyle management to help hfref patients lose weight.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old; 2. left ventricular ejection fraction (lvef) ≤40%, nyha grade ii-iii; 3. body mass index (bmi) ≥ 28 kg/m² 4. ability to use a smart phone and install the dietary management mobile app for adherence assessment through 2 weeks (± 1 week) induction period; 5. history of hospitalization for heart failure within the past 6 months; 6. signed informed consent. exclusion criteria: 1. end-stage heart failure (2 or more hospitalizations for heart failure in the past 3 months, or inability to tolerate guide-recommended drug therapy (gdmt), or positive inotropic drug dependence); 2. moderate or above anemia (hb\<90g/l); 3. renal insufficiency (egfr\<30 ml/min /1.73 m or undergoing dialysis; 4. uncontrolled thyroid disease (hyperthyroidism/hypothyroidism) or end-stage liver failure; 5. alcohol or drug abuse; 6. taking drugs for weight loss or preparing for weight loss surgery; 7. patients with malignant tumors whose life expectancy is less than 1 year; 8. situations that researchers believe may hinder compliance with the program, such as habitually ordering takeout or eating in the company cafeteria; 9. patients with planned hospitalization during the trial; 10. participating in other interventional clinical studies.
the expression of zeb1 in ctcs associated with metastasis and recurrence for gastric cancer

Conditions: Stomach Neoplasms

Summary: the aim of this study was to investigate the expression of zeb1 in ctcs for gastric cancer, its correlation with the clinicopathology of gastric cancer, and the role of zeb1 in invasion and metastasis in gastric cancer.

invasion and metastasis of tumors and postoperative recurrence are the main causes of death in patients with gastric cancer and are also the key factors affecting the clinical treatment and prognosis. in this study, the investigators will detect the expression of zeb1 in different types of ctcs(epithelial,mesenchymal and mixed phenotype) for gastric cancer by canpatroltm2 detection technology.our investigation of the relationship between zeb1 and the occurrence and development as well as the invasion and metastasis of gastric cancer is expected to provide data for the prognosis and targeted therapy of gastric cancer. approximate 100 consecutive patients with gastric cancer and ctcs(+) will be enrolled in this study.detection of zeb1 expression in ctcs at baseline will show the relationship between zeb1 and clinicopathological variables. postoperative follow-up of zeb1 expression in ctcs will be performed every three months in the first year and every six months in the following two years. the results may indicate the role of zeb1 in ctcs about invasion and metastasis for gastric cancer .the aim of this study is to clarify the clinical significance of zeb1 expression in ctcs for gastric cancer.

Eligibility criteria:
inclusion criteria: 1. pathologically proven gastric cancer and ctcs(+). 2. age:older than 18 years old,younger than 80 years old. 3. ct1-4a(surgically resectable tumor),n0-3,m0 at preoperative evaluation according to the american joint committee on cancer(ajcc) cancer staging manual seventh edition. 4. no obvious surgical contraindications. 5. american society of anesthesiology (asa) score class i, ii, or iii. 6. written informed consent. exclusion criteria: 1. severe mental disorder. 2. pregnancy. 3. history of previous gastrectomy,endoscopic mucosal resection or endoscopic submucosal dissection. 4. history of unstable angina or myocardial infarction within past six months. 5. history of previous neoadjuvant chemotherapy or radiotherapy. 6. history of other malignant disease within past 5 years.

Keywords: ctcs zeb1 gastric cancer
a long-term follow-up study of subjects who received crispr car t cellular therapies

Conditions: Hematologic Malignancy; Solid Malignancy

Summary: this study will evaluate the long-term safety and efficacy of crispr car t cellular therapies

all subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic crispr car t cellular therapy will be asked to participate in this long-term follow-up (ltfu) study. subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this ltfu study. this will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with crispr car t cellular therapies.

Eligibility criteria:
inclusion criteria: * able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document. * must have received crispr car t cellular therapy. exclusion criteria: * there are no specific exclusion criteria.
measuring physiology to determine if pre-panic attack detection is possible

Conditions: Panic Disorder

Summary: participants will be asked to wear a physiological monitoring device for 1 week and record when panic events occur. once the device is returned, the data will be downloaded and analyzed.


Eligibility criteria:
inclusion criteria: * panic disorder as described in the diagnostic and statistical manual - 5 (dsm-5) exclusion criteria: * pregnancy
evaluation of a new enteral feeding tube for the measurement of esophageal and gastric pressure

Conditions: Respiratory Failure

Summary: investigators aim to evaluate the accuracy in the measurement of the esophageal and gastric pressure of a new enteral feeding tube


Eligibility criteria:
inclusion criteria: * requiring the placement of an enteral feeding tube exclusion criteria: * esophageal ulcers * severe coagulophaty * thrombocytopenia
the effects of passive gait training in complete motor spinal cord injury (sci)

Conditions: Motor Complete Spinal Cord Injury

Summary: the purpose of this study is to determine whether a three times per week, 2 month robotic assisted treadmill gait training program, will beneficially affect the fitness, physical and psychological well-being, and the vascular and metabolic cardiovascular risk factors in individuals with complete motor spinal cord injury (sci).

cardiovascular morbidity and mortality are a source of increasing concern among people with sci and their health providers. the importance of physical activity in reducing the risk of heart disease in this population is indisputable, but exercise opportunities for persons with sci are limited by physiologic and functional factors. decreased functional muscle mass, impaired autonomic control of myocardial function, and decreased venous return limits training responses.

Eligibility criteria:
inclusion criteria: * male and non-pregnant non-lactating female * at least 6 months after injury * complete (ais a-b) cervical (c4-8) or thoracic (t1-t6) spinal cord injury according to american spinal injury association (ais) guidelines. * under 100 kg and between 155 - 200 cm of height exclusion criteria: * history of severe neurological injuries other than sci (ms, cp, als, tbi etc). * severe concurrent medical diseases: infections, heart or lung, pressure sores, etc * unstable spine or unhealed limbs or pelvic fractures * psychiatric or cognitive situations that may interfere with the trial * spasticity above 3 degree according to ashworth scale * reduced range of motion of knee/hip \> 15°

Keywords: paraplegia tetraplegia passive gait training o2 consumption exercise capacity cvd risk factors spasticity pain bladder, bowel well being
pregnancy outcomes after uterine cavity expansion

Conditions: Miscarriage; Uterus Abnormal; Infertility

Summary: this study seeks to evaluate pregnancy outcomes following hysteroscopic uterine cavity expansion surgery for patients with dysmorphic uterine cavities and poor reproductive histories. patients already planning to undergo surgery at the recommendation of their physicians will be recruited for participation.

any patient scheduled to undergo hysteroscopic expansion of the uterine cavity at rmanj is eligible to participate in the study. patients will be approached for consent to participate in the study prior to undergoing surgery. if enrolled, outcomes following surgery will be followed and recorded.

Eligibility criteria:
inclusion criteria: * any patient scheduled to undergo hysteroscopic expansion of the uterine cavity exclusion criteria: * none
maintenance dosing of vitamin d in crohn's disease

Conditions: Crohns Disease; Vitamin D Deficiency

Summary: vitamin d repletion is important for bone health in patients with crohn's disease. while repletion strategies in the general population yield similar results in those with crohn's disease, maintenance strategies are variable. high quality evidence is lacking to determine the optimal strategy to maintain adequate levels of vitamin d levels in patients with crohn's disease.

the investigators seek to identify patients with crohn's disease in clinical remission who have vitamin d levels \ 30 ng/ml) will be enrolled into the study and randomized to one of three arms: (1) placebo (2) 1000 iu/day vitamin d3 (3) 5,000 iu/day vitamin d3 for 22 weeks. based on clinical experience, doses higher than the recommended doses for bone health in the general population (600-800 iu/day vitamin d3) are needed to achieve and maintain optimal levels of vitamin d in people with crohn's disease. the investigators aim to determine optimal maintenance dosing to sustain vitamin d sufficiency in people with crohn's disease. the investigators also seek to determine demographic and disease related characteristics associated with inability to maintain sufficient levels.

Eligibility criteria:
inclusion criteria: 1. diagnosis of crohn's disease 2. in clinical remission as determined by the harvey bradshaw index (cd) ≤4 3. 25(oh)d level \<30 ng/ml within three months of study enrollment 4. prior 25(oh)d level \<30 ng/ml currently on repletion therapy 5. provided written informed consent 6. 18 years of age or older 7. all maintenance therapies required to be on stable doses for 3 months. exclusion criteria: 1. unwilling to provide consent or lack capacity 2. clinical disease activity (harvey bradshaw index \>4) 3. current pregnancy or attempting to conceive 4. hypercalcemia (must have calcium level within 6 months of enrollment) 5. known coexisting hyperparathyroidism 6. bmi \>30 kg/m² 7. history of kidney stones 8. subjects \<18 years of age - pediatric population with different recommended dosing than adults 9. non-english speakers 10. has an ileo-anal pouch or ileostomy 11. c-reactive protein greater than 2x the upper limit of normal 12. lactose intolerant 13. short gut syndrome 14. renal insufficiency (crcl \<60 ml/min) 15. concomitant therapy with thiazide diuretics, barbiturates, digitalis or supplemental products containing vitamin d 16. vitamin d levels \<30ng/ml at completion of lead in
association of preoperative sarcopenia and intraoperative hypotension in patients undergoing minimally invasive pylorus preserving pancreaticoduodenectomy : prospective observational study

Conditions: Patients Undergoing Minimally Invasive Pylorus Preserving Pancreaticoduodenectomy

Summary: the aim of this study is to determine whether preoperative sarcopenia (low muscle strength/muscle mass) is correlated with time weighted average intraoperative hypotension in patients undergoing minimally invasive pylorus preserving pancreaticoduodenectomy.


Eligibility criteria:
inclusion criteria: 1. patients 20 years or older who undergo minimally invasive pylorus preserving pancreaticoduodenectomy exclusion criteria: 1. emergency surgery 2. patients who cannot read consent forms(e.g., illiterate, foreigner, etc.) 3. patients with cognitive dysfunction 4. pregnant, lactating women 5. when hand grip test cannot be performed 6. patients with atrial fibrillation, moderate or severe valvular heart disease, left ventricular ejection fraction less than 35%
rapid-2. a study to evaluate the effectiveness of alternate dosing of procrit (epoetin alfa) in maintaining hemoglobin levels in patients with chemotherapy related anemia

Conditions: Chemotherapy; Cancer; Anemia

Summary: the purpose of this study was to determine if alternate dosing of epoetin alfa was effective in maintaining hemoglobin levels in patients with chemotherapy related anemia.

this was a retrospective chart review of patients with chemotherapy related anemia. two hundred (200) patients with chemotherapy related anemia were to have received procrit (epoetin alfa) on a weekly schedule (e.g., once every week or more frequently) for at least 4 weeks, followed by a maintenance procrit (epoetin alfa) schedule of less frequent dosing (e.g. once every 2 weeks, once every 3 weeks, or once every 4 weeks) for at least 6 weeks. hemoglobin response and maintenance of initial treatment phase hemoglobin with alternate doses of procrit (epoetin alfa) were to be evaluated.study sites were to record data in a case report form which would then be entered into a database. data was to be recorded, starting with the procrit (epoetin alfa) initiation phase (at least 4 weeks duration), and extending through at least 6 weeks of maintenance therapy. a minimum of 20 study sites were to be enrolled in the data collection process.data obtained was to be analyzed to reflect alternate dosing patterns of procrit (epoetin alfa) therapy. the frequency and percentage of patients receiving each dosing regimen were to be summarized. hemoglobin response and maintenance of initial treatment phase hemoglobin with alternate doses of procrit (epoetin alfa) were to be evaluated. if procrit (epoetin alfa) was discontinued, the time and reason(s) for discontinuation were to be recorded. patients were to have received procrit (epoetin alfa) subcutaneous injection on a weekly schedule (e.g., once every week or more frequently) for at least 4 weeks, followed by a maintenance procrit (epoetin alfa) schedule of less frequent dosing (e.g. once every 2 weeks, 3 weeks, or 4 weeks) for at least 6 weeks.

Eligibility criteria:
inclusion criteria: * patients with chemotherapy related anemia * patients with a diagnosis of malignancy * patients with initial weekly procrit (epoetin alfa) therapy for at least 4 weeks * patients must have received procrit (epoetin alfa) maintenance therapy with less frequent dosing (e.g. every 2 weeks, every 3 weeks, every 4 weeks) for at least 6 weeks immediately following once weekly dosing. exclusion criteria: * no previous diagnosis of hemolytic anemia or myelodysplasia

Keywords: procrit epoetin alfa chemotherapy related anemia
clinical implementation of tnm-immunoscore in resected non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: the purpose of this study is to validate tnm-immunoscore in resected non-small cell lung cancer.

the main aim is to validate the most promising t-cell marker candidates from earlier studies in a prospective multicenter study to establish a prognostic tnm-immunoscore. the investigators will include around 1000 stage i-iiia patients from various centers in scandinavia. the investigators will also collect demographic and clinicopathological data, blood and tissues in a database and biobank. candidate t-cell markers will be analyzed by immunohistochemistry for validation and by other methods for exploration of their impact on prognosis

Eligibility criteria:
inclusion criteria: * resectable nsclc * age 18 and above * no other malignancy last 5 years * informed consent exclusion criteria: * multiple tumor foci * preoperative chemo- or radiotherapy * non-nsclc histology * no tissue available for study * metastasis
intramyocardial multiple precision injection of bone marrow mononuclear cells in myocardial ischemia

Conditions: Heart Failure

Summary: randomised placebo-controlled study of efficiency and safety of bone marrow mononuclear cells transplantation by intramyocardial multiple precision injection in ischemic heart failure patients.

the increase of prevalence of heart failure in human population requires to develop new and effective methods of treatment. one of them is stem cells transplantation into a myocardial tissue, which cause the improvement of contractility, myocardial remodelling after myocardial infarction (mi), dilated cardiomyopathy, etc. use of autologous stem cells does not require of immunosuppressive therapy and does not correlate with some ethical problems. clinical application of mesenchymal stem cells always requires a step of culturing, which is associated with increased risk of contamination therefore haemopoietic stem cells, endothelial progenitor cells or mononuclear bone marrow cells are often used to be transplant for treatment of heart failure (hf) patients.using noga xp cardiac navigation system improves specificity of transplantations, that is decisive.

Eligibility criteria:
inclusion criteria: * patients with coronary artery disease (cad) and hf ii-iii nyha class * mi more than 6 months before the study * lvef less than 35% * absence of indication to coronary revascularization * optimal pharmacological therapy no less than 8 weeks * heart transplantation is contraindicated * patients with implantable cardioverter-defibrillator (icd) or cardiac resynchronization therapy defibrillator (crt-d) * patients giving informed consent exclusion criteria: * acute coronary syndrome * coronary revascularization less than 6 months * patients requiring surgical correction of post-mi aneurism * lv wall thickness less than 5 mm in site of possible injection * patients with crt implanted within 3 month before cells injection * clinically significant associated diseases

Keywords: heart failure bone marrow mononuclear cells